According to a report by Marks & Clerk, a law firm specializing in intellectual property, advances in biotechnology are being driven by universities and public research institutes. The most biotech patent families—“groups of patents associated with a single invention”—filed in the period 2002–2006 was 1,022, by the Japan Science and Technology Agency, followed by the […]
Prices of iron ore and nickel reached all-time highs this year, and prices for other key metals have been going strong for five years, driven in part by limited supplies and increased demand from the booming economies of China and India. Copper climbed to its highest price of $4 a pound in 2006, and is […]
According to a new report from Ernst & Young, the US biotech industry is at its strongest. Deals among US companies reached a total of $23 billion last year, and the value of mergers and acquisitions was at its second-highest level in the industry’s history. Venture capital hit an all-time high of $5.4 billion in […]
According to the National Science Foundation’s latest figures, US R&D spending grew an estimated 6.0% in 2006 to $342.9 billion, compared to 2005 growth of 7.8%. Adjusted for inflation, 2006 real R&D expenditures rose 3.5%, down from growth of 5.0% in 2005. The increase was driven by private sector spending, as real R&D spending by […]
The Pharmaceutical Research and Manufacturers of America’s (PhRMA) “2007 Pharmaceutical Industry Profile” reports that, in 2006, total sales for PhRMA member companies increased 4.2% to $245.8 billion. In 2006, PhRMA member companies spent an estimated $43.0 billion on R&D, a 7.8% increase. R&D as a percentage of sales among member companies in 2006 is estimated […]
According to the Industrial Research Institute’s (IRI) 23rd annual “R&D Trends Forecast,” R&D spending will increase in 2007. IRI’s R&D index is determined by subtracting the percentage of companies that plan to decrease or maintain their R&D spending from the percentage of companies that plan to increase their spending by at least 5%. This index […]
The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), will be granting $23 million a year for seven years to establish six Centers of Excellence for Influenza Research and Surveillance. The Centers of Excellence are located at the following institutions: St. Jude Children’s Hospital, UCLA, the […]
IMS Health reports that 2006 global pharmaceutical sales grew 7.0% to $643 billion, with “specialist-driven” products accounting for 62% of market growth. Sales in India and China increased 17.5% and 12.3% to $7.3 billion and $13.4 billion, respectively. Latin American sales grew 12.7% to $33.6 billion, and Asian-Pacific and African sales increased 10.5% to $66 […]
Investment in US refineries is on the upswing due to increased profitability. Driven by higher oil prices, rising demand and years of underinvestment, US refining margins remain healthy. According to Wood Mackenzie, US demand for gas is forecasted to outpace supply over the next three years due, in part, to shutdowns of refineries, as upgrades […]
Earlier this month, the US Department of Energy (DOE) released its final operating plan for fiscal 2007 (see IBO 2/15/07). The DOE’s budget of $23.598 billion includes $3.8 billion for the Office of Science, a 4.5% increase over the fiscal 2006 appropriation. Within the Office of Science, funding for biological and environmental research decreased 14.3% […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
